Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Show more
Location: 117 Kendrick Street, Needham, MA, 02494, United States | Website: https://www.candeltx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
291.1M
52 Wk Range
$3.79 - $14.60
Previous Close
$5.81
Open
$5.87
Volume
1,110,906
Day Range
$5.83 - $6.45
Enterprise Value
172.3M
Cash
92.17M
Avg Qtr Burn
-6.80M
Insider Ownership
17.53%
Institutional Own.
40.72%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CAN-2409 Details Intermediate/high-risk Prostate cancer | BLA Submission | |
CAN-2409 + Valacyclovir w/ SoC Details Pancreatic ductal adenocarcinoma (PDAC) | Phase 3 Initiation | |
CAN-2409 + Valacyclovir w/ ICI treatments Details Lung cancer, Cancer, Solid tumor/s, III/IV Non-small cell lung carcinoma | Phase 3 Initiation | |
CAN-2409 Details Cancer, Solid tumor/s, Low-to-intermediate-risk non-metastatic prostate cancer | Phase 2b Update | |
CAN-3110 Details Solid tumor/s, Cancer, Glioma | Phase 1b Data readout | |
CAN-2409 + Opdivo Details Cancer, Glioma, Solid tumor/s | Failed Discontinued |